KEYNOTE-B98: Phase Ib/II study of pembrolizumab plus investigational agents as second-line treatment for anti-PD-1/PD-L1-refractory extensive-stage small cell lung cancer (ES-SCLC)

Immune checkpoint inhibitors plus platinum chemotherapy are first-line standard-of-care therapy for ES-SCLC. Treatment options for patients who progress after first-line therapy have limited efficacy. The anti–PD-1 monoclonal antibody (mAb) pembrolizumab has demonstrated antitumor activity as monotherapy in patients who have received prior therapy for advanced SCLC in the KEYNOTE-028 and KEYNOTE-158 studies. KEYNOTE-B98 (NCT04938817) is a randomized, phase 1b/2, rolling-arm, multicenter, open-label study evaluating pembrolizumab plus investigational agents as second-line therapy in patients with anti–PD-1/PD-L1 refractory ES-SCLC.